Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a immune checkpoint inhibitor (ICI) by treating the patient with said ICI in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI.
Type:
Application
Filed:
December 12, 2019
Publication date:
June 23, 2022
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a immune checkpoint inhibitor (ICI) by treating the patient with said ICI in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the ICI, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the ICI.
Type:
Application
Filed:
December 12, 2019
Publication date:
October 8, 2020
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method is provided for treating a cancer patient non-responsive to treatment with a cancer therapy by treating the patient with said cancer therapy in combination with an agent that blocks the activity of a dominant factor selected among the plurality of host-driven resistance factors generated in response to treatment of the cancer patient with the cancer therapy, these factors having a fold-change predictive of a non-favorable response of the cancer patient to the treatment with the cancer therapy.
Type:
Application
Filed:
December 12, 2019
Publication date:
June 18, 2020
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method and a kit are provided for predicting a favorable or a non-favorable response of a cancer patient to treatment with a cancer therapy by determining in a biological sample obtained from the cancer patient, before and after the treatment, the changes of the levels of factors/biomarkers generated by the cancer patient in response to said treatment, and a method for treatment of a cancer patient.
Type:
Application
Filed:
December 12, 2018
Publication date:
May 9, 2019
Applicant:
Rappaport Family Institute for Research in the Me dical Sciences
Abstract: A method and a kit are provided for predicting a favorable or a non-favorable response of a cancer patient to treatment with an immune checkpoint inhibitor by determining in a biological sample obtained from the cancer patient, before and after the treatment, the changes of the levels of factors/biomarkers generated by the cancer patient in response to said treatment, and a method for treatment of a cancer patient with an immune checkpoint inhibitor.
Type:
Application
Filed:
December 13, 2018
Publication date:
April 18, 2019
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: The invention provides a method for treating cancer comprising the step of administering a therapeutically effective amount of KPC1, a peptide which is at least about 70% homologous to the KPC1 or an agent which up-regulates KPC1. In some embodiments, there is also provided a method for treating cancer comprising the step of administering a therapeutically effective amount of p50, a peptide which is at least about 70% homologous to the p50 or an agent which up-regulates p50.
Type:
Application
Filed:
January 5, 2016
Publication date:
May 24, 2018
Applicant:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Inventors:
Aaron CIECHANOVER, Yevgenia KRAVCHENKO, Inna SHOMER, Victoria COHEN
Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
Type:
Application
Filed:
November 5, 2017
Publication date:
March 1, 2018
Applicant:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Inventors:
Gera NEUFELD, Boaz Kigel, Ofra Kessler, Asya Varshavsky
Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
Type:
Grant
Filed:
September 8, 2015
Date of Patent:
November 7, 2017
Assignee:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Inventors:
Gera Neufeld, Boaz Kigel, Ofra Kessler, Asya Varshavsky
Abstract: The present invention relates to a peptide comprising an epitope within the macrophage scavenger receptor B-I, a method of using the same, a nucleic acid encoding the same and an antibody that binds to the epitope.
Type:
Application
Filed:
November 11, 2015
Publication date:
October 26, 2017
Applicant:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Abstract: Isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within the peptides. Pharmaceutical compositions including the peptides and antibodies and methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.
Type:
Application
Filed:
May 16, 2017
Publication date:
August 31, 2017
Applicants:
MOR - RESEARCH APPLICATIONS LTD., RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Inventors:
Michal A. RAHAT, Nitza LAHAT, Miriam WALTER, Haim BITTERMAN
Abstract: A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.
Type:
Grant
Filed:
May 25, 2016
Date of Patent:
August 1, 2017
Assignee:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Abstract: Isolated peptides from the protein EMMPRIN (CD147/Basigin) and antibodies directed against antigenic determinants within the peptides. Pharmaceutical compositions including the peptides and antibodies and methods of their production and use in vaccination, immunotherapy and diagnosis of proliferative, hyperpermeability, inflammatory, and angiogenesis-related diseases and disorders.
Type:
Grant
Filed:
September 30, 2014
Date of Patent:
June 27, 2017
Assignees:
MOR—RESEARCH APPLICATIONS LTD., RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Inventors:
Michal A. Rahat, Nitza Lahat, Miriam Walter, Haim Bitterman
Abstract: A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.
Type:
Grant
Filed:
April 16, 2015
Date of Patent:
April 4, 2017
Assignee:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SERVICES
Abstract: The present invention provides antibodies that differentially react with allelic variants of a polymorphic protein, methods of identifying same, an antigen binding fragment comprised therein, proteins, cells, viral particles, compositions, and kits comprising same. The invention also provides methods for determining a haptoglobin type of a subject and methods for testing a subject for susceptibility to diabetic complications.
Type:
Grant
Filed:
November 3, 2014
Date of Patent:
December 13, 2016
Assignee:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Inventors:
Jacob Victor, Noah Berkowitz, Andrew Levy
Abstract: Provided are methods and kits for determining predisposition of a subject to develop a kidney disease, by identifying in a sample of the subject at least one APOL1 polypeptide variant which is characterized by a higher trypanolytic activity on Trypanosoma brucei rhodesiense as compared to the trypanolytic activity of wild type APOL1 polypeptide as set forth in SEQ ID NO:1 on the Trypanosoma brucei rhodesiense under identical assay conditions; or at least one APOL1 nucleotide mutation in the APLO1 genomic sequence set forth in SEQ ID NO:3, wherein the at least one nucleotide mutation or polypeptide variant being in linkage disequlibrium (LD) with the S342G mutation in the APOL1 polypeptide set forth in SEQ ID NO:1, wherein presence of the APOL1 polypeptide variant indicates increased predisposition of the subject to develop the kidney disease.
Type:
Application
Filed:
April 24, 2016
Publication date:
August 11, 2016
Applicants:
Rappaport Family Institute for Research in the Medical Sciences, Ramot at Tel-Aviv University Ltd.
Inventors:
Karl SKORECKI, Shay TZUR, Saharon ROSSET, Walter Gabriel WASSER, Doron M. BEHAR, Revital SHEMER
Abstract: A method of treating a graft rejection disease in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of an isolated polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein said antigen recognition domain comprises CDR amino acid sequences as set forth in SEQ ID NO: 11, 15, 19, 23, 27 and 31, thereby treating the graft rejection disease in the subject.
Type:
Grant
Filed:
August 18, 2015
Date of Patent:
June 21, 2016
Assignee:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Abstract: A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.
Type:
Grant
Filed:
May 5, 2011
Date of Patent:
May 31, 2016
Assignee:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Abstract: The present invention relates to methods for attenuating cardiac activity, thereby treating cardiac disease and disorders associated with irregular or increased cardiac activity.
Type:
Application
Filed:
October 7, 2013
Publication date:
October 15, 2015
Applicant:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Abstract: A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed.
Type:
Grant
Filed:
July 15, 2013
Date of Patent:
October 13, 2015
Assignee:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Inventors:
Gera Neufeld, Boaz Kigel, Ofra Kessler, Asya Varshavsky
Abstract: An isolated polypeptide is provided. The polypeptide comprising an antigen recognition domain capable of specifically binding a human scavenger receptor, wherein the antigen recognition domain comprises at least three CDR amino acid sequences selected from the group consisting of SEQ ID NO: 11, 15, 19, 23, 27 and 31. Also provided are compositions which comprise the peptide and uses of same.
Type:
Grant
Filed:
June 10, 2013
Date of Patent:
September 29, 2015
Assignee:
RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES